Kalpana SHAH,Paul A. MOORE,Douglas H. SMITH,Scott KOENIG,Ezio BONVINI,Ross LA MOTTE-MOHS,Leslie S. JOHNSON
申请号：
MX2019001161
公开号：
MX2019001161A
申请日:
2018.01.29
申请国别(地区):
MX
年份:
2019
代理人:
摘要：
The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1 : PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1 -binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1 -binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.La presente invención se dirige a anticuerpos anti-PD-1 seleccionados capaces de unirse tanto a PD-1 de mono cynomolgus y a PD-1 de humano: mAb 1 de PD-1, mAb 2 de PD-1, mAb 3 de PD-1, mAb 4 de PD-1, mAb 5 de PD-1, mAb 6 de PD-1, mAb 7 de PD-1, mAb 8 de PD-1, mAb 9 de PD-1, mAb 10 de PD-1, mAb 11 de PD-1, mAb 12 de PD-1, mAb 13 de PD-1, mAb 14 de PD-1 o mAb 15 de PD-1, y a versiones humanizadas o quiméricas de tales anticuerpos. La invención pertenece de manera adicional a moléculas de unión a PD-1 que comprenden fragmentos de unión a PD-1 de tales anticuerpos anti-PD-1, inmunoconjugados, y a moléculas biespecíficas, que incluyen diacuerpos, BiTE, anticuepos biespecíficos, etc., que comprenden (i) tales fragmentos de unión a PD-1, y (ii) un dominio capaz de unir un epítopo de una molécula involucrada en regular un punto de control inmune presente en la superficie de células inmunes. La presente invención también pertenece a métodos para utilizar moléculas que se unen a PD-1 para estimular respuestas inmunes, asi com
